The global chronic bronchitis treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor which is fuelling the growth of the global chronic bronchitis treatment market includes a large patient pool with COPD diseases. According to CDC (Centres for Disease Control and Prevention) in 2018, 9.0 million adults got diagnosed with chronic bronchitis. Moreover, there are a few more factors that are playing pivotal roles to fuel the bronchitis treatment market such as an increase in the geriatric population with increased prevalence of bronchitis, rise in habits like smoking and increased levels of chemical pollutants.
Bronchitis is a respiratory disease that causes inflammation in the airways, also known as bronchi, of the lungs. It leads to irritation and inflammation of the lining of bronchial tubes, which are responsible for carrying air to and from the lungs.
The global chronic bronchitis treatment market analysis includes some of the key market players such as AstraZeneca plc., Novartis AG, GlaxoSmithKline plc., Dr Reddy's Laboratories Ltd., Sanofi S.A, and Boehringer Ingelheim International GmbH, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions.
Market Coverage
Competitive Landscape: AstraZeneca plc., Novartis AG, GlaxoSmithKline plc., Dr. Reddy's Laboratories Ltd., Sanofi S.A, among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Chronic Bronchitis Treatment Market by Segment
By Product Type
• Antibiotics
• Anti-inflammatory Drugs
• Bronchodilator
• Mucolytics
By End-User
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Chronic Bronchitis Treatment Market by Region
North America
Europe
Asia-Pacific
Rest of the World